Quantum-Si (QSI) Earnings Coverage: Complete 1Q Coverage

First reaction to QSIs earnings:

1. Product traction:
Platinum Pro officially launched and shipped, but no units/revenue per customer disclosed. Adoption remains early-stage.

2. Burn rate update:
Q1 net loss of $19.2M, free cash flow not broken out. With $232.6M on hand, runway remains into late 2027.

3. Revenue guidance or visibility?
Still no forward revenue guide. Commentary noted optimism but lacked numeric targets. Bookings or leads still vague.

4. Consumables and recurring model?
v4 Sequencing Kit is on track for Q3 2025; v3 Library Prep Kit due by year-end — both critical to consumables strategy.

5. CFO or capital plan changes?
No management changes or capital structure updates in Q1. The $50M raise in January strengthens balance sheet near term.

Bottom line: QSI executed on launch but still hasn’t delivered commercial clarity. Street will stay skeptical until revenue scales.

Earnings are now out and first reaction is QSI stock down 4.2%.

Here are the details:

Quantum-Si reported Q1 2025 revenue of $842,000, up 84% year-over-year, driven by the launch and first deliveries of its Platinum® Pro system . Gross margin improved to 58%, reflecting favorable mix, but scale remains limited. The net loss was $19.2 million, or –$0.11 per share, slightly narrower than the prior year.

Adjusted EBITDA came in at –$21.5 million, broadly in line with expectations. Operating expenses rose modestly to $25.6 million, primarily to support commercialization and development of the Proteus system and upcoming v4/v3 kits . QSI reaffirmed its cash runway into H2 2027, with $232.6 million in cash and investments on hand.

While the launch of Platinum Pro is a key milestone, adoption commentary was limited. Investors will likely be encouraged by international expansion (23 channel partners), but will want more on pipeline conversions and customer uptake.

1. Has QSI signed any new Platinum platform customers this quarter?

2. Is the burn rate improving, or still near $20M per quarter?

3. Can management offer any revenue guidance or adoption metrics?

4. How far along is the consumables strategy for recurring revenue?

5. Will the new CFO change the company’s capital priorities?

• Platinum Platform Traction: Any mention of units shipped, demos, or early customer use cases will be critical.

• Cash Burn Rate: Q1 operating cash flow and guidance on future capital needs.

• Sales Funnel Detail: Updates on signed evaluations, pipeline growth, or consumables interest.

• R&D vs. SG&A Spend: Investors will want to see a pathway toward operational leverage, even pre-revenue.

QSI has beaten EPS expectations in 3 of its last 4 quarters, but the stock’s reaction has been erratic: a –22.0% decline followed a Q3 beat, while Q4’s result sparked a +6.2% rally. Revenue has remained below $2 million in every quarter.

The weak and inconsistent reaction is driven by lack of traction in commercial adoption. Peer diagnostics and life sciences tools firms — like NanoString and 10x Genomics — have also struggled with adoption and funding gaps. QSI remains a high-risk play that needs a more credible growth trajectory to change sentiment.

QSI’s growth narrative hinges on scaling adoption of its Platinum platform — a next-gen proteomics system. The last call mentioned “early positive feedback” from initial placements, but no commercial revenue milestones.

R&D intensity remains high, with the company burning roughly $20 million per quarter. A recent CFO change has added to the uncertainty. Tonight’s call may be pivotal: if management can’t outline a clear customer acquisition pipeline or offer revenue guidance, investors may further discount the equity. Expect detailed questioning on channel development and consumables pricing strategy.

Quantum-Si operates at the intersection of biotech instrumentation and proteomics, targeting academic and pharma customers with novel single-molecule protein sequencing tech. The industry has seen strong interest in next-gen diagnostic platforms, but commercial adoption remains slow.

Illumina’s recent restructuring and Guardant Health’s sales revisions reflect broader challenges in scaling cutting-edge life sciences tools. For QSI, whose revenue remains sub-$2M per quarter, the key macro trend is the consolidation of purchasing budgets and the prioritization of clinical-ready solutions over research tools. Venture-backed startups in this space are also under pressure from high burn rates and limited access to fresh capital. Without clear signs of product-market fit, investor patience could wear thin despite the stock’s recent bounce.